TY - JOUR
T1 - APOE and cortical superficial siderosis in CAA
T2 - Meta-analysis and potential mechanisms
AU - Charidimou, Andreas
AU - Zonneveld, Hazel I.
AU - Shams, Sara
AU - Kantarci, Kejal
AU - Shoamanesh, Ashkan
AU - Hilal, Saima
AU - Yates, Paul A.
AU - Boulouis, Gregoire
AU - Na, Han Kyu
AU - Pasi, Marco
AU - Biffi, Allesandro
AU - Chai, Yuek Ling
AU - Chong, Joyce Ruifen
AU - Wahlund, Lars Olof
AU - Clifford, Jack R.
AU - Chen, Christopher
AU - Gurol, M. Edip
AU - Goldstein, Joshua N.
AU - Na, Duk L.
AU - Barkhof, Frederik
AU - Seo, Sang Won
AU - Rosand, Jonathan
AU - Greenberg, Steven M.
AU - Viswanathan, Anand
N1 - Funding Information:
This work was supported by The Genetics of Cerebral Hemorrhage with Anticoagulation study, funded by NIH/ NINDS grant R01NS059727. This study is not industry sponsored. Andreas Charidimou is supported by a Bodossaki Foundation postdoctoral scholarship.
Funding Information:
This work was supported by The Genetics of Cerebral Hemorrhage with Anticoagulation study, funded by NIH/NINDS grant R01NS059727. This study is not industry sponsored. Andreas Charidimou is supported by a Bodossaki Foundation postdoctoral scholarship.
Publisher Copyright:
© American Academy of Neurology.
PY - 2019/7/23
Y1 - 2019/7/23
N2 - ObjectiveTo assess potential mechanisms of cortical superficial siderosis (cSS), a central MRI biomarker in cerebral amyloid angiopathy (CAA), we performed a collaborative meta-analysis of APOE associations with cSS presence and severity.MethodsWe pooled data from published studies reporting APOE genotype and MRI assessment of cSS in 3 distinct settings: (1) stroke clinic patients with symptomatic CAA (i.e., lobar intracerebral hemorrhage, transient focal neurologic episodes) according to the Boston criteria; (2) memory clinic patients; and (3) population-based studies. We compared cSS presence and severity (focal or disseminated vs no cSS) in participants with ϵ2+ or ϵ4+ genotype vs the ϵ3/ϵ3 genotype, by calculating study-specific and random effects pooled, unadjusted odds ratios (ORs).ResultsThirteen studies fulfilled inclusion criteria: 7 memory clinic cohorts (n = 2,587), 5 symptomatic CAA cohorts (n = 402), and 1 population-based study (n = 1,379). There was no significant overall association between APOE ϵ4+ and cSS presence or severity. When stratified by clinical setting, APOE ϵ4+ was associated with cSS in memory clinic (OR 2.10; 95% confidence interval [CI] 1.11-3.99) but not symptomatic CAA patients. The pooled OR showed significantly increased odds of having cSS for APOE ϵ2+ genotypes (OR 2.42, 95% CI 1.48-3.95) in both patient populations. This association was stronger for disseminated cSS in symptomatic CAA cohorts. In detailed subgroup analyses, APOE ϵ2/ϵ2 and APOE ϵ2/ϵ4 genotypes were most consistently and strongly associated with cSS presence and severity.ConclusionCAA-related vasculopathic changes and fragility associated with APOE ϵ2+ allele might have a biologically meaningful role in the pathophysiology and severity of cSS.
AB - ObjectiveTo assess potential mechanisms of cortical superficial siderosis (cSS), a central MRI biomarker in cerebral amyloid angiopathy (CAA), we performed a collaborative meta-analysis of APOE associations with cSS presence and severity.MethodsWe pooled data from published studies reporting APOE genotype and MRI assessment of cSS in 3 distinct settings: (1) stroke clinic patients with symptomatic CAA (i.e., lobar intracerebral hemorrhage, transient focal neurologic episodes) according to the Boston criteria; (2) memory clinic patients; and (3) population-based studies. We compared cSS presence and severity (focal or disseminated vs no cSS) in participants with ϵ2+ or ϵ4+ genotype vs the ϵ3/ϵ3 genotype, by calculating study-specific and random effects pooled, unadjusted odds ratios (ORs).ResultsThirteen studies fulfilled inclusion criteria: 7 memory clinic cohorts (n = 2,587), 5 symptomatic CAA cohorts (n = 402), and 1 population-based study (n = 1,379). There was no significant overall association between APOE ϵ4+ and cSS presence or severity. When stratified by clinical setting, APOE ϵ4+ was associated with cSS in memory clinic (OR 2.10; 95% confidence interval [CI] 1.11-3.99) but not symptomatic CAA patients. The pooled OR showed significantly increased odds of having cSS for APOE ϵ2+ genotypes (OR 2.42, 95% CI 1.48-3.95) in both patient populations. This association was stronger for disseminated cSS in symptomatic CAA cohorts. In detailed subgroup analyses, APOE ϵ2/ϵ2 and APOE ϵ2/ϵ4 genotypes were most consistently and strongly associated with cSS presence and severity.ConclusionCAA-related vasculopathic changes and fragility associated with APOE ϵ2+ allele might have a biologically meaningful role in the pathophysiology and severity of cSS.
UR - http://www.scopus.com/inward/record.url?scp=85070183136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070183136&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000007818
DO - 10.1212/WNL.0000000000007818
M3 - Article
C2 - 31243071
AN - SCOPUS:85070183136
SN - 0028-3878
VL - 93
SP - E358-E371
JO - Neurology
JF - Neurology
IS - 4
ER -